MDNA 11
Alternative Names: MDNA-11Latest Information Update: 02 Jul 2025
At a glance
- Originator Medicenna Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins; Lymphokines; Recombinant fusion proteins
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Breast cancer; Triple negative breast cancer
Most Recent Events
- 26 Jun 2025 Updated efficacy data from a phase I/II ABILITY-1 trial in Solid tumors released by Medicenna Therapeutics
- 28 Apr 2025 Updated efficacy, adverse events and pharmacodynamics data from a phase I/II ABILITY-1 trial in Solid tumors released by Medicenna Therapeutics
- 25 Feb 2025 Pharmacodynmaics and Pharmacokinetics data from a phase I/II ABILITY-1 trial in Solid tumors released by Medicenna Therapeutics